



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

VILLEGAS *et al.*

Appl. No.: 10/721,793

Filed: November 26, 2003

For: **Recombinant Immunogens for the
Generation of Antivenoms to the
Venom of Scorpions of the Genus
Centruroides**

Confirmation No.: 6600

Art Unit: 1656

Examiner: Desai, Anand U.

Atty. Docket: 2399.0070001/JAG/LAV

**First Supplemental Information Disclosure Statement
Under 37 C.F.R. 1.97(b)**

Mail Stop RCE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **FP1** to **FP3** and **NPL1** to **NPL17** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, **US1** to **US18**, cited on the attached IDS Form, PTO/SB/08A, are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits OR before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Laura A. Vogel
Attorney for Applicants
Registration No. 55,702

Date: June 25, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

644503_1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/721,793	
			Filing Date	November 26, 2003	
			First Named Inventor	VILLEGAS, Miguel Corona	
			Art Unit	1656	
			Examiner Name	Desai, Anand U.	
Sheet	1	of	2	Attorney Docket Number	2399.0070001/JAG//LAV


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	CAIN, B.S., <i>et al.</i> , "The Physiologic Basis for Anticytokine Clinical Trials in the Treatment of Sepsis," <i>J. Am. Coll. Surg.</i> 186:337-351, American College of Surgeons (1998)	
	NPL2	DICK, A.D., <i>et al.</i> , "Neutralizing TNF-alpha Activity Modulates T-cell Phenotype and Function in Experimental Autoimmune Uveoretinitis," <i>J. Autoimmun. (Abs.)</i> 11:255-264, Academic Press (1998)	
	NPL3	FEKADE, D., <i>et al.</i> , "Prevention of Jarisch-Herxheimer Reactions by Treatment with Antibodies Against Tumor Necrosis Factor α ," <i>N. Engl. J. Med.</i> 335:311-315, Massachusetts Medical Society (1996)	
	NPL4	FOX, D.A., <i>et al.</i> , "Cytokine Blockade as a New Strategy to Treat Rheumatoid Arthritis," <i>Arch. Intern. Med.</i> 160:437-444, American Medical Association (February 2000)	
	NPL5	KRUEGER, J.G., "The immunologic basis for the treatment of psoriasis with new biologic agents," <i>J. Am. Acad. Dermatol.</i> 46:1-23, American Academy of Dermatology, Inc. (January 2002)	
	NPL6	LISMAN, K.A., <i>et al.</i> , "Managing Heart Failure with Immunomodulatory Agents," <i>Cardiol. Clin.</i> 19:617-625, W.B. Saunders Co. (November 2001)	
	NPL7	LUGER, T., "Treatment of immune-mediated skin diseases: future perspectives," <i>Eur. J. Dermatol.</i> 11:343-347, accessed at http://www.john-libbey-eurotext.fr/en/revues/medecine/ejd/e-docs/00/01/88/A6/article.md , John Libbey Eurotext (2003)	
	NPL8	MARTIN, G.S., "Current Management Strategies for Severe Sepsis and Septic Shock," Presented at Chest 2001: 67 th Annual Scientific Assembly of the American College of Chest Physicians, November 4-8, 2001, Philadelphia, PA	
	NPL9	PRESENT, D.H., <i>et al.</i> , "Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease," <i>N. Engl. J. Med.</i> 340:1398-1405, Massachusetts Medical Society (1999)	
	NPL10	QIAN, Y., <i>et al.</i> , "Topical Soluble Tumor Necrosis Factor Receptor Type I Suppresses Ocular Chemokine Gene Expression and Rejection of Allogenic Corneal Transplants," <i>Arch. Ophthalmol.</i> 118:1666-1671, American Medical Association (2000)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Equivalent of Form PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/721,793
				Filing Date	November 26, 2003
				First Named Inventor	VILLEGAS, Miguel Corona
				Art Unit	1656
				Examiner Name	Desai, Anand U.
Sheet	2	of	2	Attorney Docket Number	2399.0070001/JAG//LAV

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	STAPCYNISKI, J.S., "Shock, Septic," accessed at http://emedicine.com/EMERG/topic533.htm , eMedicine.com Inc., 25 pages (July 25, 2002)	
	NPL12	TORRES, P.F., and KIJLSTRA, A., "The role of cytokines in corneal immunopathology," <i>Ocul. Immunol. Inflamm.</i> 9:9-24, Swets & Zeitlinger (2001)	
	NPL13	ZHU, S., <i>et al.</i> , "Early Expression of Proinflammatory Cytokines Interleukin-1 and Tumor Necrosis Factor- α after Corneal Transplantation," <i>J. Interferon Cytokine Res.</i> 19:661-669, Mary Ann Liebert, Inc. (1999)	
	NPL14	English translation of Secretaría de Salud, "Potency of Anti-Poison Sera," in <i>Farmacopea de los Estados Unidos Mexicanos, Vol. II</i> , Secretaría de Salud, Mexico City, MX, pp. 1756-1757 (2000)	
	NPL15	English language translation of Secretari de Salud, "Pyrogen Tests," in <i>Farmacopea de los Estados Unidos Mexicanos, Vol. I</i> , Secretaría de Salud, Mexico City, MX, pp. 334-335 (2000)	
	NPL16	International Search Report for International Patent Application No. PCT/MX02/0013, European Patent Office, Netherlands, mailed August 16, 2002	
	NPL17	Dialog File 351, Accession No. 9271133, English language abstract for Spanish Patent No. 2 106 183	

641633_1


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/721,793
				Filing Date	November 26, 2003
				First Named Inventor	VILLEGAS, Miguel Corona
				Art Unit	1656
Examiner Name	Desai, Anand U.				
Sheet	1	of	1	Attorney Docket Number	2399.0070001/JAG/LAV

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	US1	4,806,346	02/21/1989	Hum <i>et al.</i>	
	US2	4,814,433	03/21/1989	Fredrickson	
	US3	4,849,352	07/18/1989	Sullivan <i>et al.</i>	
	US4	4,940,670	07/10/1990	Rhodes	
	US5	5,328,834	07/12/1994	Ngo <i>et al.</i>	
	US6	5,733,742	03/31/1998	Landon	
	US7	5,888,511	03/30/1999	Skurkovich <i>et al.</i>	
	US8	6,333,032	12/25/2001	Skurkovich <i>et al.</i>	
	US9	6,448,054	09/10/2002	Poznansky <i>et al.</i>	
	US10	6,534,059	03/18/2003	Skurkovich <i>et al.</i>	
	US11	6,709,655	03/23/2004	Lopez de Silanes <i>et al.</i>	
	US12	2003/0049725 A1	03/13/2003	Heavner <i>et al.</i>	
	US13	2003/0215448 A1	11/20/2003	Skurkovich <i>et al.</i>	
	US14	2003/0223995 A1	12/04/2003	Skurkovich <i>et al.</i>	
	US15	2003/0224005 A1	12/04/2003	Skurkovich <i>et al.</i>	
	US16	2003/0228310 A1	12/11/2003	Skurkovich <i>et al.</i>	
	US17	2004/0062768 A1	04/01/2004	Skurkovich <i>et al.</i>	
	US18	2004/0086508 A1	05/06/2004	Skurkovich <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	FP1	ES 2 106 183	11/01/1997	Therapeutic Antibodies Inc.		Abs
	FP2	WO 92/22324 A1	12/23/1992	Xoma Corporation		
	FP3	WO 01/58469 A1	08/16/2001	Wax <i>et al.</i>		

641621_1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.